Diabetes, other risk factors, and 12- yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434 444. 202. White SL, Chadban SJ, Jan S et al. How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ 2008; 86: 229 237. 203. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225 232. 204. Ritz E, Dikow R. Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol 2006; 2: 562 567. 205. Janka HU, Warram JH, Rand LI et al. Risk factors for progression of back- ground retinopathy in long-standing IDDM. Diabetes 1989; 38: 460 464. 206. Klein R, Klein BE, Moss SE et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 1989; 149: 2427 2432. 207. Knowler WC, Bennett PH, Ballintine EJ. Increased incidence of retino- pathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians. N Engl J Med 1980; 302: 645 650. 208. Teuscher A, Schnell H, Wilson PW. Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care 1988; 11: 246 251. 209. Gaede P, Lund-Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580 591. 210. Gaede P, Tarnow L, Vedel P et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004; 19: 2784 2788. 211. Gaede P, Vedel P, Larsen N et al. 